With this in mind, we used the Chou-Talalay median effects analysis to demonstrate that the combination of regorafenib with a PKD inhibitor resulted in a significant synergistic cytotoxic effect in CRC cells that expressed different genetic mutation profiles. This evidence concerns the gene PRKD1 and colorectal carcinoma.